Special Issue Title:

Pathogenesis, Diagnosis and Treatment of Gynaecological Tumors

Deadline for manuscript submissions: 31 January 2022

Print Special Issue Flyer (2)

Special Issue Editor

  • Guest Editor

    Zhe-Sheng (Jason) Chen, MD, PhDE-MailWebsite

    College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY, USA

    Interests: Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)

  • Guest Editor

    Zhong-qiu Lin, MD, PhDE-MailWebsite

    Obstetrics and Gynecology Memorial Hospital of Sun Yat-sen Sun Yat-sen University 107 Yan-jian West Road, Guangzhou510120, Guangdong, China

    Interests: Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Vulvar Cancer

Special Issue Information

Dear Colleagues,

Gynecological tumors are solid tumors happened in the reproductive system of women, including ovarian, cervical cancer, endometrial cancer and others. These cancers seriously affect the health of women worldwide, and contributing considerably to the global cancer burden. Many conventional anticancer drugs have been used for gynaecological tumors. For example, cisplatin, paclitaxel, methotrexate, vinorelbine and gemcitabine are often used for the treatment of gynaecological tumors. However, they may lack therapeutic effects or cause cytotoxic effects. In addition, there are many reports of gynaecological cancer progression and recurrence due to cancer cells that resist to treatments.  

Significant progress has been made in the treatment of gynecological tumors in recent years. Molecular targeted therapies have emerged as clinically useful drugs for the cure of gynaecological tumors. Molecular mechanisms of carcinogenesis and recurrence of gynecological cancers are gaining better understanding due to recent advances in molecular biology and genomic research. However, there remains a need to uncover biomarkers for prognosis and predictive diagnosis, progression and recurrence of gynecological tumors, and challenges for new therapeutics remain.

In this topic, we welcome articles for the molecular and cellular biology, biomarkers, diagnostics, and the treatment of gynaecological tumors including conventional chemotherapy, small molecular targeted drugs and monoclonal antibodies for targeted therapy. In addition, new technologies such as liquid biopsy, mRNA vaccines and gemonic editing therapy focused on gynecological tumors are also welcome.

Prof. Zhe-Sheng (Jason) Chen and Prof. Zhong-qiu Lin

Guest Editors


Cervical Cancer;Ovarian Cancer;Endometrial Cancer;Chemotherapy;Targeted Therapy

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time